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Design Preferences were determined using the Prospective Measure of Preference. 
Setting Royal Prince Alfred and St Vincent's hospitals in Sydney, Australia. 
Participants Patients with colorectal cancer were interviewed during their postoperative hospital stay, and 
physicians were asked to complete a mailed survey. 
Main Outcome Measures The Prospective Measure of Preference method produces 2 outcome measures 
of preference: willingness to trade and prospective measure of preference time trade-off. 
Results Patients' strongest preference was to avoid a stoma: more than 60% would give up a mean of 
34% of their life expectancy to avoid this surgical option. This was followed by treatment options 
involving chemoradiotherapy, where more than 50% would give up a mean of almost 25% of their life to 
avoid treatment. Surgeons held stronger preferences against all adjuvant options compared with 
oncologists (P ≤ .01). 
Conclusions Patients had strong preferences against all treatment options, and these preferences 
frequently differed from those of physicians. These results highlight the importance of determining 
patients' own preferences in the clinical encounter. Furthermore, the diversity of preferences of clinical 
subspecialists emphasizes the need for multidisciplinary treatment planning to ensure a balanced 
approach to treatment decision making for patients with rectal cancer. 
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ORIGINAL ARTICLE
Patient and Physician Preferences for Surgical
and Adjuvant Treatment Options for Rectal Cancer
James D. Harrison, BSc(Hons), MPH; Michael J. Solomon, MBBCh(Hons), MSc, FRACS;
Jane M. Young, MBBS, MPH, PhD, FAFPHM; Alan Meagher, MBBS, FRACS;
Phyllis Butow, BA(Hons), DipEd, MClinPsych, MPH, PhD; Glenn Salkeld, BBus, GDipHealthEcon, MPH, PhD;
George Hruby, MBBCh, FRANZCR; Stephen Clarke, MBBS, PhD, FRACP, FAChPM
Hypothesis: Patients and their clinicians hold varying
preferences for surgical and adjuvant treatment thera-
pies for rectal cancer.
Design: Preferences were determined using the Pro-
spective Measure of Preference.
Setting: Royal Prince Alfred and St Vincent’s hospitals
in Sydney, Australia.
Participants: Patients with colorectal cancer were in-
terviewed during their postoperative hospital stay, and
physicians were asked to complete a mailed survey.
Main Outcome Measures: The Prospective Measure
of Preference method produces 2 outcome measures of
preference: willingness to trade and prospective mea-
sure of preference time trade-off.
Results: Patients’ strongest preference was to avoid a stoma:
more than 60% would give up a mean of 34% of their life
expectancy to avoid this surgical option. This was fol-
lowed by treatment options involving chemoradio-
therapy, where more than 50% would give up a mean of
almost 25% of their life to avoid treatment. Surgeons held
stronger preferences against all adjuvant options com-
pared with oncologists (P .01).
Conclusions: Patients had strong preferences against all
treatmentoptions,andthesepreferences frequentlydiffered
fromthoseofphysicians.Theseresultshighlight the impor-
tance of determining patients’ own preferences in the clini-
cal encounter. Furthermore, the diversity of preferences of
clinical subspecialists emphasizes the need for multidisci-
plinary treatment planning to ensure a balanced approach
totreatmentdecisionmakingforpatientswithrectalcancer.
Arch Surg. 2008;143(4):389-394
F OR MORE THAN A DECADE, Adebate has surrounded theuse of adjuvant therapy forpatients with rectal cancer.This controversy has led to
distinct variations in clinical practice
guidelines and practice patterns across the
world.1-3 European trials and large meta-
analyses have demonstrated that preop-
erative and postoperative radiotherapy im-
proves local recurrence rates,4-8 and in 1
significant Swedish trial,4 preoperative
treatment improved overall long-term and
cancer-specific survival.
Although the results of randomized
trials are encouraging and help guide phy-
sicians, contention stems from the fact that
many of the reported data relate to treat-
ments administered up to 15 years ago,
when surgical techniques would be con-
sidered suboptimal by today’s standards.
Therefore, it is argued that if surgery were
optimized using current total mesorectal
excision techniques, radiotherapy may not
necessarily be indicated.9-11 This view,
however, is not supported by evidence
from the Dutch total mesorectal excision
trial,5 where total mesorectal excision was
mandated but the addition of neoadju-
vant radiotherapy still resulted in re-
duced rates of local recurrence, albeit with
no improvement in 5-year survival.
Although the potential benefits of ra-
diotherapy have been disputed, the ad-
verse effects are well recognized and may
outweigh any advantages. Many patients
will develop permanent bowel problems
greater than the normal rate of surgical ad-
verse effects,12 with short-term effects also
increased for patients receiving radio-
therapy.13,14 A particular concern associ-
ated with postsurgical irradiation to the
bowel is the potential for irreversible dam-
age that patients must live with for the re-
mainder of their lives.
There are, however, strong indica-
tions that combining postoperative radio-
therapy with concomitant chemotherapy
for stages II and III (T3-4, N0-1, M0) dis-
ease improves local recurrence and dis-
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tant metastases.15,16 Currently, efforts are being directed
at investigating the effects of combination therapy in the
preoperative setting, which are not as well defined. One
recent study17 concluded that after 5 years of follow-up,
preoperative compared with postoperative combination
therapy improved local control and was associated with
reduced toxic effects, thus enhancing the therapeutic ra-
tio. Again, any possible benefits must be weighed against
adverse effects. To the adverse effects of radiotherapy are
added further acute complications associated with che-
motherapy.
Given the lack of consensus about the role of adju-
vant therapy in rectal cancer and the quality-of-life im-
plications, patients’ own preferences or values for each
different treatment combination and outcome should be-
come a key component of clinical decision making and
informed consent. Therefore, this study was under-
taken to assess patients’ own preferences for different treat-
ment options for rectal cancer and to compare these pref-
erences with those of colorectal surgeons and medical and
radiation oncologists answering as if they themselves were
patients with rectal cancer (patient surrogates).
METHODS
Verbal scripts were developed to explain 5 treatment sce-
narios for locally advanced rectal cancer (T3-4, N0-1, M0; stage
II-III) in a standardized manner. These scenarios were chosen
because of difficulties balancing differential benefits and harms
of each treatment. Information was based on the most current
evidence available. For all the scenarios, a low anterior resec-
tion (AR) was used as the standard comparator. The 5 treat-
ment choices were (1) low AR compared with low AR plus post-
operative radiotherapy, (2) low AR compared with low AR plus
preoperative radiotherapy, (3) low AR compared with low AR
plus chemotherapy, (4) low AR compared with low AR plus
chemoradiotherapy, and (5) low AR compared with abdomi-
noperineal resection (APR). The final scenario was included
to enable patients’ preferences for each adjuvant option to be
compared with what has been documented consistently as a
surgical procedure that patients prefer to avoid.18,19
PROSPECTIVE MEASURE OF PREFERENCE
During a face-to-face interview, each treatment scenario, in-
cluding the benefits, risks, and likely long-term outcomes, was
described. Once the patient had reached a level of understand-
ing sufficient to make an informed treatment choice, patient
preferences were elicited using the Prospective Measure of Pref-
erence method.18,19 Patients were asked how much of their re-
maining life expectancy they would be willing to trade (give
up) to avoid each adjuvant therapy or an APR. The Prospec-
tive Measure of Preference method produces 2 measures of pref-
erence. The first measure is a dichotomous variable (yes/no)
of willingness to trade (WTT) any life expectancy to avoid the
nonstandard therapy and is summarized as the proportion of
the group overall that would be willing to trade. The second
measure, a prospective measure of preference time trade-off
(PMPt), is summarized as the mean proportion of remaining
life expectancy traded. Previous studies have demonstrated a
PMPt range of 0 to 0.11.18 A PMPt greater than 0.10 is a mea-
sure of a strong preference against treatment. The patient ques-
tionnaire also obtained demographic and clinical information
(age, sex, country of birth, language spoken at home, educa-
tional level, marital and employment status, number of depen-
dents, preoperative therapy, site of primary cancer, surgical pro-
cedure, and stage of disease).
DEVELOPMENT OF QUESTIONNAIRE
FOR PHYSICIANS
The same questionnaire was adapted to a self-administered for-
mat to be mailed to physicians. Physicians were asked to re-
spond as if they themselves were patients with rectal cancer (sur-
rogate patients).
VALIDATION OF QUESTIONNAIRES
The questionnaires were pilot tested to confirm test-retest re-
liability and the effect of format (face-to-face or written) on re-
sponses. Thirty clinical staff and 10 patients each completed
the questionnaire on 2 occasions, 1 week apart, with the for-
mat (written or verbal) in random order.
PATIENT RECRUITMENT AND INCLUSION
AND EXCLUSION CRITERIA
Patients with colorectal cancer (Duke stages A-C) admitted to
2 teaching hospitals for curative surgery were eligible to par-
ticipate. Patients who were cognitively impaired, who were
deemed too unwell by their treating physician, or who were
emergency admissions were considered ineligible. For non–
English-speaking patients, an interpreter was arranged through
the hospital interpreter service. Under ethical guidance, all the
patients were interviewed within a few days of surgery and at
a time before pathology results were available or definitive post-
operative treatment plans had been decided. A previous study18
highlighted that patient preferences remained stable from the
preoperative to the postoperative period.
SPECIALIST PHYSICIAN RECRUITMENT
All members of the Colorectal Surgical Society of Australasia
(colorectal surgeons) and the Medical Oncology Group of
Australia (medical oncologists) and radiation oncologists of
the Royal Australian and New Zealand College of Radiolo-
gists were surveyed. Physicians were considered ineligible if
they were not practicing medicine, were on extended leave of
more than 6 weeks, or were no longer resident in Australia.
Two reminder letters were sent to nonrespondents. Institu-
tional ethics committee approval was obtained for the study to
proceed.
STATISTICAL ANALYSIS
Statistical analysis was performed blind to participants’ group
status (patient, surgeon, or radiation or medical oncologist).
For each scenario, WTT was compared between groups using
2 tests, whereas the PMPt was compared using Wilcoxon rank
sum tests. Within-group WTT and PMPt were compared be-
tween scenarios using McNemar tests or Wilcoxon signed rank
tests as appropriate. Results were compared in patients with
colon vs rectal cancer. Independent predictors of WTT re-
sponses were assessed using logistic regression modeling. Po-
tential predictors included in the model were those exhibiting
P .25 in univariate analysis,20 and these were then sequen-
tially eliminated using a backward, stepwise approach until all
remaining predictors were significant (P .05). Analysis was
performed using a software program (SPSS; SPSS Inc, Chi-
cago, Illinois).
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SAMPLE SIZE
The WTT ranged from 0.20 to 0.54 across scenarios in a pre-
vious colorectal study.18 Assuming a similar distribution, 100
patients would be needed to estimate the PMPt, with 95% con-
fidence intervals of ±9%. To detect at least a 10% difference in
the mean PMPt, at least 36 participants were needed per group
to achieve a power of 80% at a significance level of .05 assum-




Test-retest comparisons of WTT and PMPt were highly
correlated (R=0.72-0.96) for all but 1 scenario for 1 group.
The impact of format did not affect responses, with strong
correlations (R=0.83-0.97) for all but 1 scenario for 2 pi-
lot groups.
RESPONSE RATE
Of 200 patients with colorectal cancer admitted to Royal
Prince Alfred Hospital, 103 were ineligible to partici-
pate (11 had clinical contradictions, 27 had metastatic
disease, 14 did not have an appropriate interpreter avail-
able, 9 were too unwell, 3 had died, 1 family refused ac-
cess, 20 were cognitively impaired, 4 were discharged
early, and 14 were missed/emergency admissions/not seen
by clinical nurse specialist), and 22 patients refused. Of
the 97 eligible patients, 75 consented to be interviewed
(77% consent rate). A further 28 patients were recruited
from St Vincent’s Hospital. Patients were recruited dur-
ing their postoperative hospital stay. Response rates to
the mailed survey were 79% (87 of 110) for colorectal
surgeons, 47% (97 of 206) for radiation oncologists, and
47% (80 of 169) for medical oncologists. Characteris-
tics of the patients are given in Table 1. The mean age




Patient preferences are given in Table 2. Patients’ stron-
gest preference was to avoid a stoma, with almost 65%
(WTT=0.63) of the group giving up a mean of 34%
(PMPt=0.34) of their life expectancy to avoid this option.
This was found to be significantly higher than for all other
scenarios (Wilcoxon signed rank tests, P .003). The low-
estpreferencescores (WTT = 0.43;PMPt = 0.17)were found
for preoperative radiotherapy. For 2 of the remaining op-
tions, postoperative radiotherapy and chemoradio-
therapy, patients who indicated a preference against treat-
ment did so to a large degree, as reflected by high PMPt
scores. For chemoradiotherapy, the mean amount of life
traded to avoid this treatment (PMPt=0.24) was signifi-
cantly higher than that for any other adjuvant treatment
options (all Wilcoxon signed rank tests, P .03).
Patients With Rectal vs Colon Cancer
For all the scenarios, the mean PMPt values were sig-
nificantly lower for patients with rectal cancer vs colon
cancer. Patients with colon cancer, therefore, indicated
a stronger aversion to adjuvant treatment than those with
rectal cancer. Avoidance of a stoma was a stronger pref-
erence of both groups.
Predictors of Patient Preferences
Independent predictors of WTT are given in Table 3.
A higher level of education predicted WTT for both ra-
diotherapy options, that is, a stronger preference against
adjuvant radiotherapy. After adjusting for level of edu-
Table 1. Characteristics of the 103 Study Patients




















Anterior resection 59 (57)
Abdominoperineal resection 6 (6)
Colectomy 30 (29)
Hartmann procedure 1 (1)






aPathologic abnormality determined after interview.







AR vs AR  postoperative radiotherapy 101 0.52 0.20
AR vs AR  preoperative radiotherapy 99 0.43 0.17
AR vs AR  chemotherapy 101 0.60 0.20
AR vs AR  chemoradiotherapy 100 0.52 0.24
AR vs abdominoperineal resection 99 0.63 0.34
Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.
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cation, patients with colon cancer were significantly more
likely than those with rectal cancer to trade, indicating
greater aversion to radiotherapy. For the option involv-
ing chemoradiotherapy, patients who had undergone pre-
operative treatment were less likely to trade life expec-
tancy to avoid this treatment. Furthermore, patients who
knew a relative or friend who had had an APR and lived
with a stoma were more likely to indicate a preference
against this surgical option.
Subspecialty Preferences
Physicians’ preferences are given in Table 4. The sta-
tistical significance of differences between groups is given
in Table 5. Patient and physician preferences were con-
sistently different for the scenario involving an APR, with
patients exhibiting significantly stronger preferences to
avoid this surgical option. Colorectal surgeons’ greatest
preference was to avoid postoperative radiotherapy
(WTT=0.91; PMPt=0.25), whereas radiation oncolo-
gists were less likely to trade, indicating less of an aver-
sion toward this option. High proportions of radiation
and medical oncologists were willing to trade to avoid
each treatment; however, the actual amount of years given
up ranged from 5% to 8% (PMPt=0.05-0.08), which was
much less than for surgeons and patients. Surgeons and
radiation oncologists consistently expressed divergent
preferences for options that involved radiotherapy, with
surgeons being more averse.
COMMENT
This study demonstrates that patients hold varying pref-
erences for surgical and adjuvant therapy options for rec-
tal cancer and that these preferences often do not corre-
spond with the preferences of colorectal surgeons and
oncologists answering as if they were patients themselves.
All clinical subspecialties surveyed indicated strong pref-
erences against all options presented to them. Further-
more, the amount of survival that patients and specialists
were willing to forsake to avoid adjuvant treatment was of-
ten greater than or comparable with the survival advan-
tages documented in randomized controlled trials corre-
sponding to the clinical scenarios presented.
As expected, patients were most averse to an APR, with
many willing to trade life expectancy in substantial amounts
to avoid this surgical option. The extent to which patients
were averse to this surgery was much greater than antici-
pated compared with previous studies in colorectal can-
cer and Crohn disease.18,19 Patients were significantly more
likely to be averse to an APR if they had known or knew a
patient with a stoma. This particular association, to our
knowledge, has not been previously reported and may be
a result of the negative experiences encountered by people
living with a stoma in the community.21,22
For all the adjuvant scenarios, patients who indicated a
preference against treatment did so with a strong degree
of certainty, as shown by the large proportions of life they
would give up (PMPt=0.17-0.24). Previous studies of co-
lorectal conditions18,19 have indicated that a PMPt greater
Table 3. Patient Preferences: Independent Predictors





Treatment Option: AR  Postoperative Radiotherapy
Educational level
Primary to year 10 1 [Reference]




Treatment Option: AR  Preoperative Radiotherapy
Educational level
Primary to year 10 1 [Reference]


















Abbreviations: AOR, adjusted odds ratio; APR, abdominoperineal
resection; AR, anterior resection; CI, confidence interval.
Table 4. Physician Preferences for AR and Alternative
Treatment Options





To avoid AR  postoperative radiotherapy
Colorectal surgeons 87 0.91 0.25
Radiation oncologists 76 0.60 0.05
Medical oncologists 96 0.74 0.08
To avoid AR  preoperative radiotherapy
Colorectal surgeons 85 0.79 0.12
Radiation oncologists 0.53 0.05
Medical oncologists 94 0.71 0.06
To avoid AR  chemotherapy
Colorectal surgeons 85 0.72 0.11
Radiation oncologists 85 0.70 0.08
Medical oncologists 96 0.69 0.05
To avoid AR  chemoradiotherapy
Colorectal surgeons 85 0.79 0.14
Radiation oncologists 76 0.64 0.08
Medical oncologists 95 0.72 0.07
To avoid abdominoperineal resection
Colorectal surgeons 86 0.72 0.15
Radiation oncologists 78 0.79 0.14
Medical oncologists 95 0.88 0.14
Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.
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than 0.10 is a measure of a strong preference; therefore,
for these adjuvant options, patients expressed particularly
strong views. The large amount of life patients were will-
ing to give up to avoid treatment is also significant con-
sidering the elderly demographic of this patient group. Pa-
tients would more likely trade to avoid options involving
chemotherapy. This finding is consistent with a previous
study18 exploring patient views of treatment for colon can-
cer and most probably reflects concerns for the effects of
treatment on quality of life.
The results of this study suggest that if patients are
offered adjuvant therapy they would most likely opt for
preoperative radiotherapy. From a patient’s perspective
it is plausible that preoperative treatment may be viewed
as a more favorable option because of its relatively short
duration compared with other regimens and the fact that
treatment may be complete once surgery has been per-
formed. Furthermore, any potential damage to the bowel
due to presurgical irradiation is likely to be removed dur-
ing surgery, which is appealing from a quality-of-life per-
spective. The preference for preoperative treatment may
also be a reflection of coping style among patients whereby
those who have a problem-focused coping style may pre-
fer to “get all the treatment over with” as quickly as
possible.23,24
In this study, patients with rectal cancer were more
willing to accept all adjuvant treatment options, as in-
dicated by lower WTT and PMPt values, compared with
patients with colon cancer. Furthermore, the site of can-
cer was found to be an independent predictor of prefer-
ence for both radiotherapy options. This finding high-
lights that the choices and values of patients who are
actually facing the treatment decisions differ from those
who are not. Although some of this variation can be ex-
plained by cognitive dissonance reduction25 in the group
of patients with rectal cancer who had preoperative treat-
ment (n=11), this cannot explain all the difference. These
findings have important methodological implications for
future studies and emphasize the importance of recruit-
ing actual patients to quantify preferences.
Specialists’ preferences were generally significantly
higher than those of patients, particularly among sur-
geons. Differences in preferences between patients and
physicians are not uncommon, and this finding is con-
sistent with other studies in colorectal,18 breast,26 and pros-
tate cancer27 and end-of-life decisions.28 Concordance of
50% to 80% has been reported,27 and it has been shown
that predictions of treatment preferences more closely re-
semble the views of the surrogate than the actual pref-
erences of the individual facing treatment. Although it
is acknowledged that physicians have to make decisions
for their patients on an individual basis, such discor-
dance may have implications for clinical decision mak-
ing and patient referral pathways. Specialist treatment rec-
ommendations remain an important predictor of treatment
choice, with patients likely to ask their physicians for the
treatment they would prefer.29,30 The present study sug-
gests that surgeons acting as patient surrogates would be
less likely to recommend adjuvant therapy. It is also plau-
sible that such strongly held preferences may affect the
likelihood that surgeons refer their patients to oncology
consultations. These attitudes may partially explain why
currently in Australia there is less than 40% concor-
dance with 2 national clinical guidelines that recom-
mend the use of adjuvant treatment for some patients with
rectal cancer.31
A limitation of this study is the low response rates from
oncologists. Each of the societies surveyed has a broad
membership base, so the survey was likely mailed to phy-
sicians with little interest in or experience with rectal can-
cer. However, previous studies18 involving these groups
have reported similar response rates, with respondents
most likely interested in gastrointestinal tract disorders.
This study also was performed before the Swedish Rec-
tal Cancer Trial4 reported long-term survival benefits, so
these data could not be included in the treatment sce-
narios. However, the issues of optimal surgical tech-
niques and the impact of treatment on quality of life re-
main unresolved.
In conclusion, patients and physicians were able to
trade life expectancy to indicate a preference for various
Table 5. Statistical Significance of Differences Between
Patients, Surgeons, and Radiation and Medical Oncologists
for Alternative Treatment Optionsa
Comparison Group WTTb PMPtc
To avoid AR  postoperative radiotherapy
Patients vs colorectal surgeons .001 .01
Patients vs radiation oncologists .16 .03
Patients vs medical oncologists .001 .26
Colorectal surgeons vs radiation oncologists .001 .001
Colorectal surgeons vs medical oncologists .01 .001
Radiation vs medical oncologists .09 .16
To avoid AR  preoperative radiotherapy
Patients vs colorectal surgeons .001 .07
Patients vs radiation oncologists .18 .30
Patients vs medical oncologists .001 .74
Colorectal surgeons vs radiation oncologists .001 .001
Colorectal surgeons vs medical oncologists .14 .001
Radiation vs medical oncologists .02 .02
To avoid AR  chemotherapy
Patients vs colorectal surgeons .001 .62
Patients vs radiation oncologists .001 .99
Patients vs medical oncologists .001 .54
Colorectal surgeons vs radiation oncologists .84 .51
Colorectal surgeons vs medical oncologists .52 .001
Radiation vs medical oncologists .67 .01
To avoid AR  chemoradiotherapy
Patients vs colorectal surgeons .001 .94
Patients vs radiation oncologists .08 .11
Patients vs medical oncologists .01 .17
Colorectal surgeons vs radiation oncologists .04 .01
Colorectal surgeons vs medical oncologists .23 .001
Radiation vs medical oncologists .35 .87
To avoid abdominoperineal resection
Patients vs colorectal surgeons .26 .01
Patients vs radiation oncologists .03 .01
Patients vs medical oncologists .001 .01
Colorectal surgeons vs radiation oncologists .26 .40
Colorectal surgeons vs medical oncologists .01 .11
Radiation vs medical oncologists .11 .46
Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.
aTest statistics are available from the authors on request.
bP value for 2 test.
cP value for Wilcoxon rank sum test.
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adjuvant and surgical options for rectal cancer. Patients
had strong preferences against all treatment options, and
they frequently differed from those of physicians. These
results highlight the importance of determining pa-
tients’ own preferences in the clinical encounter. Fur-
thermore, the diversity of preferences of clinical subspe-
cialists emphasizes the need for multidisciplinary
treatment planning to ensure a balanced approach to treat-
ment decision making for patients with rectal cancer.
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